Proliferative Diabetic RetinopathyNCT01478763
Vitrous Analysis in Proliferative Diabetic Retinopathy
An observational study of Proliferative Diabetic Retinopathy, run by Anders Kvanta at 1 site in Sweden.
Trial summary
Analysis of vitreous proteins in patients undergoing pars plana vitrectomy for proliferative diabetic retinopathy Read more about this study
- Who is it for?
- Ages 12 years and older
- Conditions the study is for
- Proliferative Diabetic Retinopathy
- How many people
- 200 participants
- Where
- 1 siteSweden
- Study dates
- Jan 2011to Sep 2014
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 12 years and older
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: Patients undergoing pars plana vitrectomy for proliferative diabetic retinopathy
Who may be able to join
- proliferative diabetic retinopathy with vitreous hemorrhage
Who cannot join
- vitreous hemorrhage of other cause than proliferative diabetic retinopathy
- previous vitrectomy
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Analysis of Vitreous Proteins in Patients Undergoing Pars Plana Vitrectomy for Proliferative Diabetic Retinopathy
Analysis of vitreous proteins in patients undergoing pars plana vitrectomy for proliferative diabetic retinopathy
Read the detailed description
To analyse and compare vitreous proteins in patients undergoing pars plana vitrectomy for proliferative diabetic retinopathy.
- Conditions
- Proliferative Diabetic Retinopathy
- Keywords
- PDRP, vitreous, protein, vitrectomy
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted23 Nov 2011 (estimated)
- Study startJan 2011
- Primary completionSep 2014
- Study completionSep 2014
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Proliferative Diabetic RetinopathyStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 200 participants (actual)
Sponsor and investigators
- Lead sponsor
- Anders Kvanta
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, Anders Kvanta, St. Erik Eye Hospital
- Investigators
- Anders Kvanta, PhD, Principal investigator, St. Erik Eye Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01478763
- Sponsor's protocol ID
- Vitreous1
- Status last verified
- Sep 2014
- First submitted
- 21 Nov 2011
- Last updated
- 25 Sep 2014
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 25 Sep 2014. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Analysis of Vitreous Proteins in Patients Undergoing Pars Plana Vitrectomy for Proliferative Diabetic Retinopathy
- ClinicalTrials.gov ID
- NCT01478763
- Acronym / sponsor ID
- Vitreous1
- Conditions
- Proliferative Diabetic Retinopathy
- Keywords
- PDRP, vitreous, protein, vitrectomy
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 200 participants (actual)
- Lead sponsor
- Anders KvantaUniversity, hospital or other
- Study start
- Jan 2011
- Primary completion
- Sep 2014 (actual)
- Study completion
- Sep 2014 (actual)
- First posted
- 23 Nov 2011 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Analysis of vitreous proteins in patients undergoing pars plana vitrectomy for proliferative diabetic retinopathy
Detailed description
To analyse and compare vitreous proteins in patients undergoing pars plana vitrectomy for proliferative diabetic retinopathy.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
Who may qualify
- Ages
- 12 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- Patients undergoing pars plana vitrectomy for proliferative diabetic retinopathy
Key inclusion criteria (1 listed)
- proliferative diabetic retinopathy with vitreous hemorrhage
Key exclusion criteria (2 listed)
- vitreous hemorrhage of other cause than proliferative diabetic retinopathy
- previous vitrectomy
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Not reported in the source record.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 25 Sep 2014.
Related trials for Proliferative Diabetic Retinopathy
Not yet recruitingPhase 4
Continuous Delivery of Ranibizumab Via the Port Delivery System for Proliferative Diabetic Retinopathy-related Vitreous Hemorrhage With Pars Plana Vitrectomy and Limited PRP.
Proliferative Diabetic Retinopathy, Diabetic Retinopathy
Active, not recruitingPhase 2
A Study to Evaluate the Efficacy and Safety of Orally Administered VX-01
Diabetic Retinopathy, NPDR - Non Proliferative Diabetic Retinopathy
RecruitingPhase 3
Faricimab + PRP vs. Vitrectomy + Endolaser for Treatment of PDR
Proliferative Diabetic Retinopathy (PDR)
Active, not recruitingPhase 2
Single-site Pilot Study Evaluating the Effect of QLS-111 Ophthalmic Solution on Posterior Perfusion and Vessel Dilation
Non-proliferative Diabetic Retinopathy (NPDR), Open-angle Glaucoma (OAG)
Recruiting
Early Vitrectomy vs PRP in Early Proliferative Diabetic Retinopathy
Proliferative Diabetic Retinopathy (PDR)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Anders Kvanta, PhD principal investigator
St. Erik Eye Hospital
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Proliferative Diabetic Retinopathy, run by Anders Kvanta at 1 site in Sweden.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 25 Sep 2014. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Sweden. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 Sep 2014; AzTrials last refreshed its copy on 31 Oct 2026.